#IDJClub Transcript
Healthcare social media transcript of the #IDJClub hashtag.
โ ().
See #IDJClub Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | ID Journal Club @IDJClub Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Ilan Schwartz MD PhD @GermHunterMD RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub @Cortes_Penfield #IDJClub this is @BradCutrellMD from @UTSWNews in Dallas |
| ID Journal Club @IDJClub @Cortes_Penfield: I have no COI relevant to this paperโ this discussion coming to you from outside the pocket of Big Rifapentine ;) 1st author is my colleague @UNMC_ID, but this paper = consensus pick from @DocWoc71, @TMcCarty2010, @GermHunterMD & I did not suggest it. #IDJClub |
 | Julio C. Zuniga-Moya @JulioCZuniga1 RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Laila Woc-Colburn, MD @DocWoc71 @IDJClub @Cortes_Penfield @UNMC_ID @TMcCarty2010 @GermHunterMD Same here no COI #IDJClub this @DocWoc71 all the way from Houston |
| Ilan Schwartz MD PhD @GermHunterMD @IDJClub @Cortes_Penfield Ilan Schwartz here from Edmonton, Alberta, currently jetlagged in Europe #idjclub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub @Cortes_Penfield @UTSWNews No COI here either #IDJClub |
 | Joe Wang @JoeWangDO RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Sanjat Kanjilal @SanjatKanjilal @IDJClub @Cortes_Penfield #IDJClub Hi all, Sanjat Kanjilal from the @DeptPopMed at @harvardmed and the @BrighamWomens in Boston |
 | Laura Marks @LauraMarks5 RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Madeline King-Patel @MK_IDpharm @IDJClub @Cortes_Penfield Madeline, in Philadelphia ๐ #idjclub |
 | Swapnil Hiremath @hswapnil@bsky.social @hswapnil Swapnil Hiremath Am a nephrologist from @OttawaMedicine #NephJC cofounder Just popping in to say hi, and best wishes to #IDJclub https://t.co/2UbUMyLMwY |
 | FOAMid @foamid @IDJClub @Cortes_Penfield @UNMC_ID @DocWoc71 @TMcCarty2010 @GermHunterMD Milana here. Joining in for the beginning. No COI. Such a great idea to have this! #IDJClub |
| Ilan Schwartz MD PhD @GermHunterMD RT @foamid: @IDJClub @Cortes_Penfield @UNMC_ID @DocWoc71 @TMcCarty2010 @GermHunterMD Milana here. Joining in for the beginning. No COI. Such a great idea to have this! #IDJClub |
| ID Journal Club @IDJClub Letโs start with questions. Q1: of the currently-recommended regimens for treatment of LTBI, what do you use most often? (No need to restrict answers to people living w/ HIVโ but if your answer is different by serostatus, feel free to share how & why) #IDJClub |
| ID Journal Club @IDJClub Q2: What do you see as the main problems w/ treating LTBI, either in folks w/ HIV or the general pop? Adherence, toxicities, drug interactions, something else? Before we look at the study: if 1mo INH-rifapentine worked as well as 9mo INH, would you use it? Prefer it? #IDJClub |
| Ilan Schwartz MD PhD @GermHunterMD RT @hswapnil: Swapnil Hiremath Am a nephrologist from @OttawaMedicine #NephJC cofounder Just popping in to say hi, and best wishes to #IDJclub https://t.co/2UbUMyLMwY |
 | Don Branam @Branamycin RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Ahmed Babiker ุฃุญู
ุฏ ุจุงุจูุฑ @Ahmed_HBabiker @IDJClub @Cortes_Penfield Ahmed Babiker , ID trained med micro fellow at Emory . Will be lurking/absorbing info while cooking dinner. Looking forward to the discussion ! #IDJClub |
 | Ahmed Abdul Azim @triplea87 @IDJClub @TomSchmidt30 @Cortes_Penfield Ahmed here, ID fellow @BIDMChealth Boston. My first #IDJClub. Apologies if I turn into a wallflower for this one. |
 | Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub A2: I think the biggest struggles are duration and adherence, regardless of HIV sero-status. #IDJClub |
 | Jennifer Cuellar Rodrรญguez @JennCuellarR RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
| Ilan Schwartz MD PhD @GermHunterMD RT @IDJClub: Letโs start with questions. Q1: Letโs start with questions. Q1: of the currently-recommended regimens for treatment of LTBI, what do you use most often? (No need to restrict answers to people living w/ HIVโ but if your answer is different by serostatus, feel free to share how & why) #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @triplea87 @IDJClub @TomSchmidt30 @Cortes_Penfield @BIDMChealth Everyone's first #IDJClub, so no worries! Participate as you feel comfortable! |
| Madeline King-Patel @MK_IDpharm @IDJClub A2. All of the above are concerns^ esp DDI W/ ART. Shorter durations work well for lots of infections... if the work well for LTBI, thatโs great! #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub #IDJClub adherence for the 6-9 month regimens, drug interactions for the rifamycin containing regimens. Yes would definitely use 1 month regimen if non inferior |
| ID Journal Club @IDJClub Next, letโs review BRIEF TB. The study asked if 1mo QD INH + rifapentine was non-inferior to 9mo QD INH for preventing either TB dz OR death from TB or unknown cause in folks w/ HIV & (LTBI or residence in high-TB area) over >3yr. NI margin set @ 1.25 events/100 pt-yrs #IDJClub |
 | Adi @IDdocAdi @IDJClub @Cortes_Penfield Lurking in the background, Adi, ID fellow #IDJClub |
| Joe Wang @JoeWangDO @IDJClub @Cortes_Penfield @UNMC_ID @DocWoc71 @TMcCarty2010 @GermHunterMD Joe Wang, med/Peds resident from Omaha, looking forward to this! #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 1st question of the night @UCLA_ID @UNMC_ID @iupedsID @UofA_ID @OHSU_ID @onnnedu @Tacats99 #IDJClub |
| Ilan Schwartz MD PhD @GermHunterMD @IDJClub I get mostly referrals of LTBI in transplant candidates. If there is time pre-tx (and you never really know) I try to squeeze in 4 mo rif but otherwise 9 mo INH post-tx due to interactions with anti-rejection medโs #idjclub |
| Laila Woc-Colburn, MD @DocWoc71 Question 2 thoughts @CarlosdelRio7 @GlobalTB @tb #IDJClub |
| ID Journal Club @IDJClub Enter the controversy: Stout et al argue BRIEF TBโs inclusion of mostly pts with a neg LTBI test (despite good CD4s) biases the study toward non-inferiority. The authors counter: PPD -ve PLWH in high-TB areas have TB rates >100-fold higher than in the US. What do #IDJClub think? |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 RT @IDJClub: Enter the controversy: Enter the controversy: Stout et al argue BRIEF TBโs inclusion of mostly pts with a neg LTBI test (despite good CD4s) biases the study toward non-inferiority. The authors counter: PPD -ve PLWH in high-TB areas have TB rates >100-fold higher than in the US. What do #IDJClub think? |
| Julio C. Zuniga-Moya @JulioCZuniga1 RT @IDJClub: Letโs start with questions. Q1: Letโs start with questions. Q1: of the currently-recommended regimens for treatment of LTBI, what do you use most often? (No need to restrict answers to people living w/ HIVโ but if your answer is different by serostatus, feel free to share how & why) #IDJClub |
 | Antibiotic Steward Bassam Ghanem ๐
ฑ๏ธC๐๐
ฟ๏ธ๐ @ABsteward NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: Aiming for the Developing Antibiotics for Resistant Targets (DART) ๐ฏ #IDTwitter #medtwitter cc #IDJClub https://t.co/D4EVahSL9G https://t.co/8ba3RwzRPU |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub Question is results relevant for whom. Very relevant for those who live in countries with high endemic rates of TB, more questionable for other places. Only about 700 of those enrolled had positive PPD or IGRA so smaller numbers there #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub Definitely a fair criticism, but not sure how to do it differently. Can only imagine how long the trial would take to enroll if positive test was required. #IDJClub |
| ID Journal Club @IDJClub Great point. Let me put the screws to you, though, Dr. Cutrell: in your opinion, are these data sufficient to inform treatment choice for PPD or IGRA positive folks living in the US? #IDJClub |
 | Greg Perry @ID_GregPerry RT @IDJClub: Great point. Let me put the screws to you, though, Dr. Cutrell: Great point. Let me put the screws to you, though, Dr. Cutrell: in your opinion, are these data sufficient to inform treatment choice for PPD or IGRA positive folks living in the US? #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub Similarly, is the follow-up duration enough to be convinced? Can you lengthen without potentially complicating with re-infections? I'd be suspect. #IDJClub |
| ID Journal Club @IDJClub Great point. And one of the important points of this study IMO is that adherence in INH arm was 90% when in real life it's more like 50% - so 9mo INH efficacy if anything may be OVERestimated #IDJClub |
 | Anthony Cannella, MD, Msc, FACP @apc_md RT @IDJClub: Great point. And one of the important points of this study IMO is that adherence in INH arm was 90% when in real life it's more like 50% - so 9mo INH efficacy if anything may be OVERestimated #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub I think they probably are but ...I am sure we will get into one of the other limitations which is that the lower than expected event rate in control and experimental arms makes it underpowered #IDJClub |
| Greg Perry @ID_GregPerry RT @IDJClub: Great point. And one of the important points of this study IMO is that adherence in INH arm was 90% when in real life it's more like 50% - so 9mo INH efficacy if anything may be OVERestimated #IDJClub |
| ID Journal Club @IDJClub OK, letโs look at what BRIEF TB found. In the mITT analysis, 2% of the pts in the 1mo INH-RPT arm met the primary end point vs 2% in the 9mo INH arm (between group difference -0.2 cases/100pt-yrs with upper bound 0.3/100pt-yrs, meeting prespecified NI criteria) #IDJClub |
 | Sandra Rajme @SandraRajme @IDJClub @Cortes_Penfield Hi! Iโm Sandra from Mexico. ID fellow, first #IDJClub. |
| Laila Woc-Colburn, MD @DocWoc71 RT @IDJClub: Great point. And one of the important points of this study IMO is that adherence in INH arm was 90% when in real life it's more like 50% - so 9mo INH efficacy if anything may be OVERestimated #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub I wonder more about the low rate of ART utilization, viral suppression of the patients included in the trial. Could the data actually be better in a country with low risk of re-infection? #IDJClub |
| ID Journal Club @IDJClub One pt with RIF-resistant TB dz per group. Similar AE rate (6% vs 7% in 1mo vs 9mo) but pts more likely to pause/stop therapy 2/2 an AE in the 9mo INH arm (OR 2.0; 95% CI 1.3-3.3) & more grade 3-4 & targeted safety events in 9mo arm (4.6 vs 2.9 / 100pt-yr). Thoughts? #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 Here is a poll to settle the controversy of the BRIEF tB inclusion thoughts @sargsyanz @thecurbsiders @JennCuellarR @RushCCH_ID @MarAzizID1 @SamDoc813 @UVA_ID @aliciaelr #IDJClub |
| ID Journal Club @IDJClub Perhaps! It is worth noting that a bunch of the folks who did not start the trial on ART initiated it after enrollment. Also worth noting ART had to start off as EFV or NVP-based... yeesh |
 | Jamie Kisgen @KisgenUF RT @ABsteward: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: Aiming for the Developing Antibiotics for Resistant Targets (DART) ๐ฏ #IDTwitter #medtwitter cc #IDJClub https://t.co/D4EVahSL9G https://t.co/8ba3RwzRPU |
| Ilan Schwartz MD PhD @GermHunterMD @IDJClub Of course there is more opportunity to discontinue over 9 mo than over 1 mo... But I think the fact that >90% completed 9 mo of INH is remarkable. #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub Higher adherence rates and less pause due to AEs is expected and very plausible with the 1 mo regimen. Major question is whether true non inferiority of efficacy can be established given lower event rate making it underpowered. #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 RT @IDJClub: One pt with RIF-resistant TB dz per group. Similar AE rate (6% vs 7% in 1mo vs 9mo) but pts more likely to pause/stop therapy 2/2 an AE in the 9mo INH arm (OR 2.0; 95% CI 1.3-3.3) & more grade 3-4 & targeted safety events in 9mo arm (4.6 vs 2.9 / 100pt-yr). Thoughts? #IDJClub |
| ID Journal Club @IDJClub Great point re: time bias. I also wondered if, given that most pts were in high-endemicity settings- could 9mo INH have "overperformed" because it was preventing new infections over a longer period? #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub These data are what we want/expect the trial to confirm. Longer durations are problematic. Nobody really doubts that, and you wonder how far off real life that >90% adherence in the 9 month regimen really is. #IDJClub |
 | Sรฉbastien Poulin @sebpoule @IDJClub @Cortes_Penfield Sรฉbastien Poulin, Med micro and ID, North shore of Montreal (p.s.children are sleeping... for now ๐๐) #IDJclub |
| ID Journal Club @IDJClub No because I am not that handy with stats / power calculations (also I hate having to admit this in public). Now or later, can anyone in the community help? #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @IDJClub #IDJClub definitely think this represents the ideal outcomes that could be expected from the 9 month regimen INH and kudos to the entire trial team for the follow up and adherence |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 RT @IDJClub: No because I am not that handy with stats / power calculations (also I hate having to admit this in public). Now or later, can anyone in the community help? #IDJClub |
| ID Journal Club @IDJClub Q3: At the end of the day, what do you think about BRIEF TB? Are you worried re: power & want another trial? Ready to implement 1mo INH-RPT in people with a CD4 >250 but not CD4 <250? #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @Tacats99 @IDJClub Excellent point, and one brought up during our @UABSOM ID Board Review Conference today. Goal of tx isn't 0% risk of reactivation. If shorter looks to be as good with improved safety/adherence, is that enough of a risk/benefit balance to change practice? I suspect so. #IDJClub |
 | Michael Ison @MichaelIsonMD RT @GermHunterMD: Less than 90 minutes until inaugural #IDTwitter journal club!!! Join us at the hashtag #IDJClub at 9 EST to discuss the BRIEF TB trial @IDJClub https://t.co/YRjT8C2xnd |
| Brad Cutrell, MD, FIDSA @BradCutrellMD #IDJClub A bit tangential but it seems like we have an epidemic in medicine in general of large RCTs that take years to design and run where historical data used to estimate event rates that way underestimate actual events due to trends in medical std care. |
| Ilan Schwartz MD PhD @GermHunterMD @BradCutrellMD bingo, and they are all non-inferiority designs (and almost always "prove" non-inferiority)! #IDJClub |
| ID Journal Club @IDJClub IMO not tangential at all. Given the amount of research dollars that go into a single well-designed large multicenter RCT, shout it from the rooftops. #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD #IDJClub how do we get better at making power estimates? It was not a fatal flaw in this case but is a shame when large expensive trials fail to give clarifying answer |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub Yes, with aggressive initiation of ART for all patients! That's probably a more beneficial act than LTBI treatment for the vast majority. #IDJClub |
 | The Curbsiders @thecurbsiders RT @DocWoc71: Here is a poll to settle the controversy of the BRIEF tB inclusion thoughts @sargsyanz @thecurbsiders @JennCuellarR @RushCCH_ID @MarAzizID1 @SamDoc813 @UVA_ID @aliciaelr #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 Q3 for #IDJClub regarding statitical anaylysis ๐๐ผ what does the audience say @drjootz @josh_nosanchuk @EvaClarkMD @FirasElChaer @JillWeather @adarsh_bhimraj @davidvanduin @belga_sara |
| Anthony Cannella, MD, Msc, FACP @apc_md @BradCutrellMD Agreed...this happens even in the translational research realm too m, especially when I comes to a topic rarely investigated... #idjclub @IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @BradCutrellMD How do you alter this though? Should we see it as further reassurance for shortening therapy (to a point)? If we're generally doing better regardless of treatment chosen, should we feel more reassured to choose shorter regimens? #IDJClub |
| Anthony Cannella, MD, Msc, FACP @apc_md Agreed...this happens even in the translational research realm too, especially when it comes to a topic rarely investigated... #idjclub @IDJClub |
| Greg Perry @ID_GregPerry RT @IDJClub: Great point re: Great point re: time bias. I also wondered if, given that most pts were in high-endemicity settings- could 9mo INH have "overperformed" because it was preventing new infections over a longer period? #IDJClub |
| ID Journal Club @IDJClub Q4: For those of you onboard w/ the conclusions of BRIEF TB, any reason the results canโt be extrapolated to folks who donโt have HIV? Would you use 1mo INH-RPT to expedite care in pts with LTBI when asked โwhen can we give the patient biologics/chemo/a transplantโ? #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @SanjatKanjilal @Tacats99 @IDJClub @UABSOM Agreed! It's always stuck with me that in the ICU zero re-intubations is seen as wrong, as it signifies ventilation lasting too long, but we don't have this same level of risk acceptance for other conditions. How do we change the paradigm? #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @GermHunterMD @IDJClub Agreed, especially in the era of INSTIs and minimal drug-drug interactions. #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @jlsalinas7 @IDJClub Agreed completely. Question is does it tell us anything useful about LTBI Rx in the US in PLWH or not? #IDJClub |
| ID Journal Club @IDJClub RTCs are great but a side effect of making them the holy grail of EBM is that we reduce therapeutic decisions into results of a few primary outcomes. Obv in real life prescribing is more complex. I bet most ID docs would give up some LTBI tx efficacy for 1 vs 9mo of tx #IDJClub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @IDJClub A4: I'd like to think so, especially given that a large portion of the enrolled patients had uncontrolled HIV... should at least be able to extrapolate to the un-immunosuppressed awaiting mAb/transplant/etc. Would be pretty hesitant, want a lot of shared decision making #IDJClub |
 | Brad Spellberg @BradSpellberg RT @ABsteward: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: Aiming for the Developing Antibiotics for Resistant Targets (DART) ๐ฏ #IDTwitter #medtwitter cc #IDJClub https://t.co/D4EVahSL9G https://t.co/8ba3RwzRPU |
| Madeline King-Patel @MK_IDpharm @IDJClub This seems like the ideal place in therapy to me #IDJClub |
| Brad Cutrell, MD, FIDSA @BradCutrellMD @SanjatKanjilal Exactly. We need to be smarter about designing trials that can be nimble and maximize chances of meaningful information (positive or negative) while maintaining validity and scientific rigor #IDJClub |
| Anthony Cannella, MD, Msc, FACP @apc_md @IDJClub I would agree with this; was at @UCSDMedSchool previously. 9mo of INH. Was difficult for people who traveled back and forth over the border for work. Higher endemic area than most in US. a pilot study there would provide better data for US in general. #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 Thoughts about using 1mo INH-RPT in immunocompromised patients...transplant? @camwolfe @RicardoLaHozMD @DocSaimaAslam @belga_sara @MarionHemmersb1 @EmilyBlumbergMD @BarbAlexanderMD @PergamIC ? #IDJClub #IDTwitter #IDMedEd |
| Sรฉbastien Poulin @sebpoule @TMcCarty2010 @GermHunterMD @IDJClub Still many problems with Rifampin and INSTI. Ex; 2x DLG. No go for Bic. I donโt know for Rifapentine ๐ค BUT maybe DLG + Rifapentine = โ? (What about Bic?) https://t.co/utpzzFvrfH #IDJclub |
| ID Journal Club @IDJClub @SAIRABT Interesting! Was this paradoxical rxn to treatment? Drug-drug interaction? I have not seen this w/ any rifamycin but haven't used much rifapentine yet. #IDJClub |
| ID Journal Club @IDJClub Agree this is a big problem with INSTIs being the backbone of therapy. Could this be... potentially an actual reason to use doravirine??? |
 | Chris Bland @blandman19 RT @ABsteward: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: NEW ๐ฅ๐ฅ @BradSpellberg @TravisBNielsen @AnnalsofIM Ensuring Sustainability of Needed Antibiotics: Aiming for the Developing Antibiotics for Resistant Targets (DART) ๐ฏ #IDTwitter #medtwitter cc #IDJClub https://t.co/D4EVahSL9G https://t.co/8ba3RwzRPU |
| Anthony Cannella, MD, Msc, FACP @apc_md @sebpoule @TMcCarty2010 @GermHunterMD @IDJClub Great point... #idjclub |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 @sebpoule @GermHunterMD @IDJClub Fascinating, hadn't seen this! #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 @IDJClub Less is better as we are learning. It is easier to do 1mo vs 9mo. Even complex MDR TB regimens are being shorten or made easier to take. Yes stigma still exists with our TB pts. #IDJClub |
| Laila Woc-Colburn, MD @DocWoc71 @SAIRABT @IDJClub Depends on the patient population. The older and maybe a touch of NASH/cirrhosis donโt do as well as younger patients. The high dose of INH RPT sometimes is not as well tolerated #IDJClub |
| ID Journal Club @IDJClub Thanks to everyone who participated in #IDtwitterโs 1st #IDJClub! I learned a ton & much appreciated your commentary. Weโll figure out how to record the discussion & carve out a space for it on https://t.co/w6wK82z0Y3 so stay tuned for that and news about next monthโs session! |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 RT @IDJClub: Thanks to everyone who participated in #IDtwitterโs 1st #IDJClub! I learned a ton & much appreciated your commentary. Weโll figure out how to record the discussion & carve out a space for it on https://t.co/w6wK82z0Y3 so stay tuned for that and news about next monthโs session! |
| ID Journal Club @IDJClub I will hang around for a while to keep discussing before going back to being plain old @Cortes_Penfield. HUGE thank you to everyone who took time to come out & sorry if I missed your introduction #IDJClub |
| Ilan Schwartz MD PhD @GermHunterMD Thank you @Cortes_Penfield for doing a fantastic job in moderating our first #IDJClub!!! |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 If anyone has suggestions for a paper, we're definitely open. Expect to hear more soon! cc: @Cortes_Penfield @GermHunterMD @DocWoc71 |
| Laila Woc-Colburn, MD @DocWoc71 Itโs a wrap for the 1st article #IDJClub stay tune ๐ก for our next article, suggestions always welcome @davidvanduin @PergamIC @josh_nosanchuk @DrJeanneM @DrJRMarcelin @KellyCawcuttMD @Payal_Patel @JillWeather @CarlosdelRio7 @PaulSaxMD @RazonableMD @FranciscoMarty_ @BradCutrellMD |
| ID Journal Club @IDJClub @chrisreiskobal @GermHunterMD @Cortes_Penfield Thank you for joining us! We just about finished the live part but search #IDJClub for Qs and please add in your thoughts! Discussion will keep rolling for another few days I am sure |
| Anthony Cannella, MD, Msc, FACP @apc_md Bravo! Glad to see this up and running and to interact with you! #IDJClub ๐ |
| Sรฉbastien Poulin @sebpoule @IDJClub Not sure ๐ค Quick Lexicomp check. Any pharmacist input ? #IDJclub https://t.co/vc62NJwkle |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 RT @IDJClub: Welcome everyone to the inaugural #IDJClub! We'll have a new topic & moderator each month. Tonight it's @Cortes_Penfield here & we're discussing the BRIEF-TB trial. Please use #IDJClub to help us keep track of the conversation. Let's start with introductions! Who's joining in? https://t.co/gnZlM9B88A |
 | Chris Kobal @chrisreiskobal RT @GermHunterMD: Less than 90 minutes until inaugural #IDTwitter journal club!!! Join us at the hashtag #IDJClub at 9 EST to discuss the BRIEF TB trial @IDJClub https://t.co/YRjT8C2xnd |
| Todd McCarty ๐๐๐จโโ๏ธ @TMcCarty2010 RT @GermHunterMD: Thank you @Cortes_Penfield for doing a fantastic job in moderating our first #IDJClub!!! |
#IDJClub content from Twitter.